Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 21;14(7):2157.
doi: 10.3390/jcm14072157.

Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials

Bryam López Tuesta  1 , Camila A Arones-Santayana  2 , Gustavo A Valderrama Sáenz  3 , Yerson Alberca-Naira  4 , Hector I Cedillo Torres  5 , Abdias Baltazar Castellanos  6 , Daniel B Müller Quintanilla  3 , Judith Yangali-Vicente  7 , Joshuan J Barboza  8
Affiliations
Review

Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials

Bryam López Tuesta et al. J Clin Med. .

Abstract

Introduction: Impetigo is a relatively common superficial infection of the skin and soft tissues. Although its prevalence is more significant in childhood, it might also occur in adulthood, affecting the quality of life of our patients. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ozenoxacin 1% with placebo or mupirocin was conducted. Databases searched included PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model, and heterogeneity was assessed using I2 statistics. Results: Four RCTs with 754 patients met the inclusion criteria. Ozenoxacin significantly improved the clinical success (RR: 1.14, 95% CI: 1.04-1.26, and I2 = 0%) and reduced the clinical failure (RR: 0.54, 95% CI: 0.39-0.75, and I2 = 0%) compared to the placebo. Microbiological success was also superior (RR: 1.31, 95% CI: 1.05-1.58, and I2 = 4%), while the microbiological failure was significantly lower (RR: 0.31, 95% CI: 0.21-0.46, and I2 = 0%). Comparisons with mupirocin showed similar efficacy, though the estimates were less precise. Conclusions: Ozenoxacin 1% is an effective treatment for impetigo, significantly improving clinical and microbiological outcomes while reducing the failure rates compared to the placebo. Its efficacy is comparable to mupirocin, suggesting it as a viable alternative for first-line therapy. Given the low heterogeneity observed, these findings support the clinical use of ozenoxacin for impetigo management. Future large-scale RCTs and direct comparative studies are warranted to further validate its therapeutic benefits.

Keywords: adolescents; adults; children; impetigo; ozenoxacin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
PRISMA 2020 [16]: Flowchart of the selection of studies.
Figure 2
Figure 2
RoB 2.0 for bias assessment [4,14,15].
Figure 3
Figure 3
Effects of ozenoxacin 1% on the clinical success [4,14,15].
Figure 4
Figure 4
Effects of ozenoxacin 1% on the clinical failure [4,14,15].
Figure 5
Figure 5
Effects of ozenoxacin 1% on the microbiological success [4,14,15].
Figure 6
Figure 6
Effects of ozenoxacin 1% on the microbiological failure [4,14,15].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bell L., Whyte A., Duysburgh C., Marzorati M., Van den Abbeele P., Le Cozannet R., Fança-Berthon P., Fromentin E., Williams C. A randomized, placebo-controlled trial investigating the acute and chronic benefits of American Ginseng (Cereboost®) on mood and cognition in healthy young adults, including in vitro investigation of gut microbiota changes as a possible mechanism of action. Eur. J. Nutr. 2022;61:413–428. - PMC - PubMed
    1. Flores R., Villarroel J.L., Valenzuela F. Enfrentamiento de las infecciones de piel en el adulto. Rev. Med. Clin. Condes. 2021;32:429–441. doi: 10.1016/j.rmclc.2021.06.004. - DOI
    1. Sladden M.J., Johnston G.A. Common skin infections in children. BMJ. 2004;329:95–99. doi: 10.1136/bmj.329.7457.95. - DOI - PMC - PubMed
    1. Rosen T., Albareda N., Rosenberg N., Alonso F.G., Roth S., Zsolt I., Hebert A.A. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018;154:806–813. doi: 10.1001/jamadermatol.2018.1103. - DOI - PMC - PubMed
    1. Torrelo A., Grimalt R., Masramon X., Albareda López N., Zsolt I. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents. Dermatology. 2020;236:199–207. doi: 10.1159/000504536. - DOI - PMC - PubMed

LinkOut - more resources